Overall rank by patents
#2,668
of 49,997 tracked assignees
USPTO PatentsView assignee record - 146 granted patents across 14 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).
The verdict
According to USPTO PatentsView, Sangamo ranks #2,668 of 49,997 tracked US assignees by granted-patent volume, with 146 patents across 14 technology areas.
USPTO PatentsView assignee plate
Corpus R2668 · US Corporation #2,668 · 146 grants
GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL
Nearest grant-volume peer: Safran Transmission Systems (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Clover Network · near
42 score
First Principles · near
42 score
Innovex Downhole… · near
42 score
Sangamo Therapeutics · this assignee
42 score
Simple Living… · near
42 score
3D Lighting… · lowest
7 score
What this shows Sangamo's Innovation Score is 41.8/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Sangamo Therapeutics, Inc. is a focused PatentsView assignee: 14 CPC subclasses with 97.9% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2018 (26 grants) versus a trough of 7 in 2024. By volume, Sangamo sits between Safran Transmission Systems and Clark Equipment Company.
From 2019–2021 to 2022–2024, Sangamo Therapeutics, Inc. moved from 67 to 39 grants (0.58x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,492. See the growth leaderboard.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Safran Transmission Systems
146 patents
Shenzhen Royole Technologies Co., Ltd.
146 patents
Spin Memory, Inc.
146 patents
Samsonite IP Holdings S.a r.l.
146 patents
ScienBiziP Consulting(Shenzhen)Co., Ltd.
146 patents
Sangamo Therapeutics, Inc.
146 patents
Abbott Point of Care Inc.
145 patents
Analogic Corporation
145 patents
Clark Equipment Company
145 patents
What this shows Sangamo holds 146 patents at rank #2,670, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #2,670 in granted patent volume.
Other assignees with the most granted patents in Sangamo's primary technology class.
Two PlainPatent-derived peer sets for Sangamo, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (42 here).
Nearest assignees by average claims per patent (12.3 here).
Sangamo's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
42 Top 32% higher than 68% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 13 | 8.9% |
| 2018 | 26 | 17.8% |
| 2019 | 23 | 15.8% |
| 2020 | 24 | 16.4% |
| 2021 | 20 | 13.7% |
| 2022 | 14 | 9.6% |
| 2023 | 18 | 12.3% |
| 2024 | 7 | 4.8% |
| 2025partial year | 1 | 0.7% |
Top 14 of 14 technology areas
Overall rank by patents
#2,668
of 49,997 tracked assignees
41.8 out of 100
What to do with this data
Sangamo Therapeutics, Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.